BioCentury
ARTICLE | Clinical News

CAR-NKG2D: Phase I started

May 4, 2015 7:00 AM UTC

Cardio3 began an open-label, U.S. Phase I trial to evaluate single doses of IV CAR-NKG2D in about 24 patients with acute myelogenous leukemia (AML) or multiple myeloma (MM). Patients will receive dose...